BSE filing, NSE: SAVFI. Summary written from the filing by ALFA Finder's alert engine.
Mantra Capital Ltd: key numbers
- Share price
- ₹16.51
- Market cap
- ₹59.15 Cr
- Revenue (annual)
- ₹16.32 Cr
- Net profit (annual)
- ₹-13.46 Cr
- P/E (TTM)
- -5.9×Sector 19.7×
- Promoter holding
- 67.08%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mantra Capital Ltd
All →Mantra Capital Convertible Warrants
No fund deviation reported on Mantra Capital's conversion of 15 lakh warrants into equity, worth ₹1.50 Crore. The warrants were issued to promoter MD Deepa Tracy.
- Value
- ₹1.50 Cr
Mantra Capital Q2 FY27 Results: Turns Profitable, Net Profit ₹1.8 Cr
Mantra Capital Ltd reported revenue from operations of ₹5.9 Cr (+73.5% YoY) and net profit of ₹1.8 Cr for Q2 FY27.
- Key figure
- Net profit ₹1.8 Cr
Mantra Capital Other Announcement
Mantra Capital Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Mantra Capital Convertible Warrants
Mantra Capital allotted 30,00,000 equity shares to Mrs. Deepa Kishor Tracy upon conversion of warrants for ₹3 Crore.
- Value
- ₹3.00 Cr
Mantra Capital Board Meeting Date
Mantra Capital Limited has scheduled a board meeting for October 26, 2026. The board will consider unaudited standalone financial results for the half-year ended September 2026.
Mantra Capital Annual Report
Mantra Capital has resubmitted its Annual Report for FY 2025-26. The revision is limited only to changing the document layout to portrait orientation.
Other board meeting date announcements
All →Patel Engineering Board Meeting Date
Patel Engineering has scheduled its Board meeting for November 5, 2026, to approve Q1 and H1 FY27 unaudited results. No financial figures or decisions are reported in this advance notice.
GKB Ophthalmics Board Meeting Date
GKB Ophthalmics scheduled its Board Meeting for November 12, 2026. The meeting will consider approving unaudited results for the September 30, 2026 quarter and half year.
Bombay Oxygen Investments Board Meeting Date
Board meeting scheduled for Nov 6, 2026 to approve Q1 and H1 FY27 unaudited results. Trading window closed for insiders Oct 1–Nov 8, 2026.
OCCL Board Meeting Date
OCCL Ltd has scheduled its Board meeting for 6 November 2026 to consider Q1 FY27 unaudited results and a possible interim dividend. The trading window for designated persons closed from 1 October 2026.
TCM Board Meeting Date
TCM Limited intimated a Board meeting for 06/11/2026 to approve Q2 FY27 results. The trading window will reopen 48 hours after the results declaration.
Mercury Laboratories Board Meeting Date
Mercury Laboratories scheduled its Board meeting for November 5, 2026, to approve Q2/H1 FY27 results. Trading window remains closed until 48 hours post-announcement.